Follicum AB: Abstract accepted for poster presentation at the International Investigative Dermatology Conference in Orlando, May 16-19 2018

Follicum AB (“Follicum” or “the Company”) a clinical stage company focused on developing a novel peptide to promote hair growth, today, May 7, announces that an abstract has been accepted for poster presentation during the International Investigative Dermatology Conference to be held in Orlando, USA May 16-19 2018. The abstract will be presented by Follicum’s partner, ImaBiotech - a CRO with innovative imaging services. The details of the abstract can be found below.

Poster session: Poster Display session.
Poster number: 128.
Link to abstract: click here.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
Email: info@follicum.com

About ImaBiotech
ImaBiotech supports pharmaceutical industry with innovative Imaging services that predict more accurately which treatment will work in stratified population. ImaBiotech is a Contract Research Organization (CRO) with two facilities one in Boston (MA) and one in France. The company offers innovative services to the pharmaceutical research to provide better drug efficacy and toxicity evaluations from preclinical to clinical stages, making better and safer drugs. www.imabiotech.com

About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. www.follicum.com